Quest’s Profitable Moment
President Donald Trump is going to Davos for the World Economic Forum — and he’s taking many members of his cabinet with him. Davos is famous for being a gathering of heads of state as well as CEOs and other high-powered corporate executives. Considering Trump’s “drain the swamp” platform, it is a bit eye-raising that he will be attending an event that personifies global elites.
The White House says President Trump will be there to discuss his “America First” policy. What this means exactly is not clear. I think it is safe to assume there will be some carrots and some sticks in his approach. The visit will be part victory lap…reminding the participants that his election was a rejection by U.S. voters of what Davos is all about. Treasury Secretary Steven Mnuchin hinted that would be the case, saying before the trip that the president was not there to rub elbows with the rich.
Sign up for the weekly Quest newsletter in your inbox
Top 5 Clean Energy Stocks To Invest In 2018: Pilot Gold Inc (PLGTF)
- [By SEEKINGALPHA.COM]
Wesdome Gold (OTC:WDOFF) is confirming the potential of its Kiena Deeps discovery with the latest batch of drill results from this venue. Itinerant Musings subscribers who joined us in this trade will be pleased. Treasury Metals (OTC:TSRMF) needs to find more underground ore to justify a construction decision of its Goliath gold project, and it’s doing just that as reported in the latest news release and explained in this article. NuLegacy Gold (OTCQX:NULGF) finally announced results from the twin hole of the Avocado discovery. A detailed discussion will be forthcoming for Itinerant Musings subscribers shortly. Pilot Gold (OTCPK:PLGTF) is making progress at its Goldstrike project in Utah. The latest set of results confirmed the Peg Leg and Covington targets as valid targets for further drilling. Arizona Mining (OTC:WLDVF) is countering controversy by releasing more drill results, and reporting the discovery of Taylor Deeps. The roller coaster continues.
Top 5 Clean Energy Stocks To Invest In 2018: Eli Lilly and Company(LLY)
- [By WWW.THESTREET.COM]
Bond prices were much lower early in the day, with yields up by nearly 10 basis points. But fixed income has rallied back (reducing the drop by half on the day). Valeant Pharmaceuticals (VRX) , more weakness. Large pharma lower, led by Eli Lilly (LLY) . Old tech lags, with International Business Machines (IBM) , Intel (INTC) , Cisco Systems (CSCO) and Microsoft (MSFT) all lower. Media roughed up a bit (CBS (CBS) and Comcast (CMCSA) ). The Ugly
Gold down another $23 to $1,188 (SPDR Gold Trust ETF (GLD) down $2.25). Urban Outfitters (URBN) down $5. NOTE: There will be no “Takeaways” today! Happy Thanksgiving. Position: Long GLD small, SDS large, JCP large; short SPY, CSCO, CAT small, IWM, TLT small.
- [By Chris Lange]
Eli Lilly & Co. (NYSE: LLY) saw its shares in free fall on Wednesday, not from the usual rhetoric of politicians or even the election, for that matter, but a late-stage trial failure. As 24/7 Wall St. has said time and again, clinical trials can make or break biotech and pharma companies. In this case Eli Lilly hit new 52-week lows, not seen since 2014 and this will not be a loss that Eli Lilly will easily forget. Effectively, the company announced results from its Phase 3 solanezumab trial in people with mild dementia due to Alzheimers disease (AD).
- [By The Ticker Tape]
Overall, first-quarter earnings have been pretty positive and many CEOs struck an optimistic tone discussing outlooks for the remainder of 2017. Two industrial bellwethers, General Electric Company (NYSE: GE) and Honeywell International Inc. (NYSE: HON), just beat Wall Street analyst expectations on Friday and credit card companies American Express Company (NYSE: AXP) and Visa Inc (NYSE: V) also reported strong results—some are taking that as a sign that consumer confidence could be translating into consumer buying. Next up in Q1, Eli Lilly and Co (NYSE: LLY), Lockheed Martin Corporation (NYSE: LMT), and Caterpillar Inc. (NYSE: CAT) report before market open on April 25.
- [By Ben Levisohn]
Following the decision of the PTAB not to institute CHRS IPR on the 166 Humira formulation patent, we continue to anticipate that first likely launch of biosimilar adalimumab (Humira) in the US will be delayed until 2020, in line with our published forecasts and biosimilar model. We anticipate the open IPR hearings for the 135 dosing patent on Humira (filed by Boehringer and Coherus) to begin in Feb 2017 with the ruling in May. We rateAbbVie a Buy. We continue to prefer BUY rated Bristol-Myers Squibb (BMY), Eli Lilly (LLY) among the US names.
- [By WWW.THESTREET.COM]
Cramer recalled recently investing in Eli Lilly (LLY) on hopes the company’s Alzheimer’s research would be worth billions. As time has worn on, Lilly’s obstacles to success seem to be mounting. Not knowing if or when Lilly might see success, Cramer said he sold the stock and moved on.
- [By Johanna Bennett]
Eli Lilly & Co. (LLY) and Biogen (BIIB) are far from the only two drug makers racing to deliver a new treatment for Alzheimers disease. But they are pretty much leading the pack.
The market for an effective therapy that actually slows the progression of the disease would likely generate billions of dollars in annual sales. It is quite literally the drug industrys version of the holy grail.
And according to Barclays analysts Geoff Meacham and Paul Choi, the next few weeks could prove to be one of the most fertile periods in Alzheimers disease research since 2008.
We think the most likely outcome for Lilly’s Phase 3 EXPEDITION 3 (E3) solanezumab trial is the primary cognition (ADAS-Cog14) endpoint is met (just achieving statistical significance with a p-value <0.05) and mixed results on the secondary endpoints including function (ADL), which we believe should be good enough to support a regulatory submission. While aducanumab has a marginally different mechanism of action, we nevertheless expect BIIB shares to trade in sympathy to Lilly.
Implications for Biogen and Merck: The E3 results are likely to result in volatility for Biogen (up 20-30%, down 10-15%) as Alzheimer’s drives both long-term growth and M&A value even though aducanumab works differently from solanezumab.
Aducanumab dose titration data is expected at the CTAD meeting (San Diego, Dec. 9). Merck’s Phase 2/3 EPOCH verubecestat (BACE) trial is scheduled to finish in June 2017 but unlike E3, PET scans/CSF tests for A were not an inclusion criteria. We think Merck shares could move 3% to 5% in either direction in sympathy to E3.
At $76.58, Lillys share price has fallen more than 9% over the past year, while Biogen has climbed more than 9% over the same span.
Top 5 Clean Energy Stocks To Invest In 2018: AVG Technologies N.V.(AVG)
- [By Igor Novgorodtsev]
InterActiveCorp (IACI) bought Ask.com for $1.85 billion in 2005. The new Perion will be worth only about 40% of that. After the merger, Perion will leapfrog its much larger rivals: Babylon and AVG (AVG). Finally, Perion should be able to increase its operating margins as it can spread its SG&A costs over a much larger base (Conduit EBITDA margin is 32% vs. Perion’s 23%). Perion will keep its senior management team intact: Josef Mandelbaum will remain its CEO and Yacov Kaufman its CFO. Perion has successfully orchestrated a roll-up acquisitions of privately-held Sweetpacks and Smilebox, so I have high confidence that they know how to integrate a new business.
Top 5 Clean Energy Stocks To Invest In 2018: JP Energy Partners LP(JPEP)
- [By WWW.GURUFOCUS.COM]
For the details of ArcLight Capital Partners, LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=ArcLight+Capital+Partners%2C+LLC
These are the top 5 holdings of ArcLight Capital Partners, LLCEnable Midstream Partners LP (ENBL) – 43,585,926 shares, 67.58% of the total portfolio. American Midstream Partners LP (AMID) – 13,977,709 shares, 19.28% of the total portfolio. Shares added by 230.89%TransMontaigne Partners LP (TLP) – 3,166,704 shares, 13.14% of the total portfolio. JP Energy Partners LP (JPEP) – 0 shares, 0% of the total portfolio. Shares reduced by 10000%Added: Am
Top 5 Clean Energy Stocks To Invest In 2018: Callon Petroleum Company(CPE)
- [By Lisa Levin]
Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.